PMID- 33553254
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210210
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 7
DP  - 2020
TI  - Prognostic Value of Circulating sST2 for the Prediction of Mortality in Patients 
      With Cardiac Light-Chain Amyloidosis.
PG  - 597472
LID - 10.3389/fcvm.2020.597472 [doi]
LID - 597472
AB  - Aims: Systemic light-chain (AL) amyloidosis is a multisystemic disorder leading 
      to multiple organ dysfunction and mortality that is often caused by cardiac 
      involvement. Soluble suppression of tumorigenicity 2 (sST2) is a novel biomarker 
      identified for risk stratification of heart disease. The aim of this study was to 
      investigate the value of circulating sST2 levels in prognosis and mortality risk 
      assessments for the AL amyloidosis population. Methods and Results: A total of 56 
      patients diagnosed with AL amyloidosis were enrolled in Peking Union Medical 
      College Hospital (PUMCH) from January 2015 to May 2018. The relationships between 
      the clinical parameters and overall survival (OS) and risk factors for disease 
      progression were assessed. Additionally, receiver operating characteristic (ROC) 
      curves, Kaplan-Meier analysis, and Cox hazard models were performed to explore 
      the predictive value of sST2 in mortality rates. We found that the median OS of 
      all patients was 7.3 [interquartile range (IQR) 4.4, 15.9] months. The median 
      baseline sST2 level was 12.2 (IQR 5.1, 31.1) ng/ml, and the sST2 high group had 
      more severe patients with a higher Mayo stage. In the ROC analysis, the area 
      under the curve (AUC) was 0.728 [95% confidence interval (CI) 0.603-0.853] for 
      sST2 to predict the outcomes of AL amyloidosis patients, and the optimal cutoff 
      value was 12.34 ng/ml (sensitivity 80.2%, specificity 61.1%). Moreover, in 
      multivariate Cox proportional hazards regression analysis, sST2 acted as an 
      independent predictor of poor functional outcome in patients with AL amyloidosis. 
      Conclusion: In AL amyloidosis patients, sST2 was a strong and independent 
      prognostic biomarker for all-cause mortality, providing complementary prognostic 
      information of a novel scoring system for risk stratification.
CI  - Copyright (c) 2021 Zhang, Xiao, Liu, Fang, Tian, Li, Zhou, Xie, Dong and Zhang.
FAU - Zhang, Yang
AU  - Zhang Y
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Xiao, Ying
AU  - Xiao Y
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Liu, Yongtai
AU  - Liu Y
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Fang, Quan
AU  - Fang Q
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Tian, Zhuang
AU  - Tian Z
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Li, Jian
AU  - Li J
AD  - Department of Hematology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Zhou, Daobin
AU  - Zhou D
AD  - Department of Hematology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Xie, Zhongpeng
AU  - Xie Z
AD  - Department of Pathology, Hainan General Hospital, Haikou, China.
FAU - Dong, Ruijia
AU  - Dong R
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Zhang, Shuyang
AU  - Zhang S
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20210120
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC7855859
OTO - NOTNLM
OT  - biomarker
OT  - heart failure
OT  - overall survival
OT  - soluble ST2
OT  - systemic light chain amyloidosis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/02/09 06:00
MHDA- 2021/02/09 06:01
PMCR- 2020/01/01
CRDT- 2021/02/08 05:47
PHST- 2020/08/24 00:00 [received]
PHST- 2020/12/07 00:00 [accepted]
PHST- 2021/02/08 05:47 [entrez]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2021/02/09 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2020.597472 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2021 Jan 20;7:597472. doi: 10.3389/fcvm.2020.597472. 
      eCollection 2020.